文献速递口腔修复与种植口腔颌面外科

高剂量抗骨吸收药物治疗癌症患者牙种植前瞻性可行性研究:2年随访

Dental implant treatment in patients with cancer on high-dose antiresorptive medication: A prospective feasibility study with 2 years follow-up.
PubMed 文献 · Clin Oral Implants Res · 2023-10-24

这项前瞻性可行性研究评估了接受高剂量抗骨吸收药物(HDAR)的癌症患者种植治疗,2年负载后种植体生存率100%、成功率97.4%,口腔健康相关生活质量在各组均提高,2例发生MRONJ但与种植无关,结论认为在该人群可行但需谨慎。

要点

  • HDAR癌症患者种植体2年生存率100%、成功率97.4%。
  • 治疗后口腔健康相关生活质量在各组均提高。
  • 2例发生MRONJ但与种植治疗无关。

核心结论

  • HDAR癌症患者种植治疗2年负载后生存率和成功率高、生活质量提高,可行但应谨慎对待普遍推荐。

研究设计与样本

  • 前瞻性可行性研究,纳入三组HDAR患者:既往拔牙无MRONJ、既往MRONJ已愈合、现存MRONJ计划手术切除。
  • 种植体不附加骨或软组织增量,≥12周行基台手术,≥14周开始修复,随访6个月、1年和2年。

主要发现

  • 2年负载后总体种植体生存率100%,成功率97.4%。
  • OHLQoL在所有组治疗后均提高,第3组提高幅度较大。
  • 2例患者发生MRONJ,但与种植治疗无关。

关键数值与推荐

  • 种植体2年生存率100%,成功率97.4%。
  • 基台手术在≥12周进行,修复治疗在≥14周开始。
  • OHLQoL采用OHIP-49和QLQ-H&N35问卷分析。

临床怎么用

  • 对HDAR癌症患者可考虑种植治疗,但需个体化评估并谨慎应用普遍推荐。
  • 可预期较高的短期种植体生存率和成功率以及生活质量改善。

局限性

  • 为可行性研究,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Dental implant treatment is considered contraindicated in patients with cancer on high-dose antiresorptive medication (HDAR). The aim of this prospective, feasibility study was to evaluate implant treatment in patients with cancer on HDAR, in terms of implant survival, implant success, and oral health-related quality of life (OHLQoL) after 2 years of loading. MATERIALS AND METHODS: Implants were inserted in three groups of HDAR patients: (1) Previous tooth extraction, no medication-related osteonecrosis of the jaw (MRONJ), (2) Previous MRONJ, now healed, (3) Existing MRONJ, planned surgical resection. Implants were placed without adjunctive bone or soft tissue argumentation. Abutment operation was performed after ≥12 weeks. Prosthetic treatment was initiated ≥14 weeks. Survival and success rate were determined, and OHLQoL was analyzed with OHIP-49 and QLQ-H&N35 questionnaires. Patients were seen for 6 months, 1- and 2 years follow-up. RESULTS: Twenty-two patients, 39 implants, completed the implant-based prosthetic treatment. Implant-supported crowns and overdentures were fabricated. Thirteen patients (59%) with 23 implants (59%) completed 2 years follow-up. Overall implant survival and success rate after 2 years of loading were 100% and 97.4%, respectively. OHLQoL for the patients increased in all groups after the treatment, a substantial increase was seen in group 3. Two patients developed MRONJ, but not related to the implant treatment. CONCLUSION: Dental implant treatment, with high survival and success rate and increased post-treatment OHLQoL, is feasible in HDAR patients after 2 years of loading. Caution with general recommendations should be exercised.

来源:Clin Oral Implants Res,查看原文。版权归原作者所有。

引用

  1. Hjortholt CO, Andersen SWM, Jensen SS, et al. Dental implant treatment in patients with cancer on high-dose antiresorptive medication: A prospective feasibility study with 2 years follow-up. Clin Oral Implants Res. 2023. PMID: 37873916. doi:10.1111/clr.14197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。